CF PharmTech Inc, a company in Suzhou Industrial Park-Xiangcheng District Cooperative Economic Development Zone, went public on the Main Board of the HKEX on Oct 8.
Founded in 2007 with a registered capital of RMB371 million, CF PharmTech is dedicated to developing, manufacturing and marketing high-end inhalable drugs for respiratory diseases.
The company’s global offering comprises 41,198,000 H-shares, priced at HK$14.75 per share, with an estimated net proceeds of approximately HK$525.4 million. The raised fund will be allocated to the ongoing R&D and clinical development of existing inhalable drug candidates for domestic and international markets, preclinical research for multiple other pipeline projects and technologies, as well as the expansion and upgrade of production facilities, equipment procurement and manufacturing management systems.
October 8, 2025
